Technical Analysis for KYMR - Kymera Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Down |
Historical KYMR trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | -4.43% | |
NR7 | Range Contraction | -4.43% | |
Wide Bands | Range Expansion | -4.43% | |
Down 3 Days in a Row | Weakness | -4.43% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Trending on StockTwits | about 7 hours ago |
Down 5% | 1 day ago |
60 Minute Opening Range Breakdown | 1 day ago |
Down 3% | 1 day ago |
Down 2 % | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Diseases Rheumatoid Arthritis Autoimmunity Hematologic Malignancies Dermatitis Atopic Dermatitis Hidradenitis Suppurativa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Diseases Rheumatoid Arthritis Autoimmunity Hematologic Malignancies Dermatitis Atopic Dermatitis Hidradenitis Suppurativa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 91.92 |
52 Week Low | 25.43 |
Average Volume | 369,150 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 52.35 |
20-Day Moving Average | 43.20 |
10-Day Moving Average | 36.51 |
Average True Range | 3.96 |
ADX | 35.33 |
+DI | 12.20 |
-DI | 33.01 |
Chandelier Exit (Long, 3 ATRs ) | 48.97 |
Chandelier Exit (Short, 3 ATRs ) | 44.76 |
Upper Bollinger Band | 60.18 |
Lower Bollinger Band | 26.22 |
Percent B (%b) | 0.21 |
BandWidth | 78.61 |
MACD Line | -5.40 |
MACD Signal Line | -5.10 |
MACD Histogram | -0.3011 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 36.04 | ||||
Resistance 3 (R3) | 36.14 | 35.37 | 35.60 | ||
Resistance 2 (R2) | 35.37 | 34.71 | 35.32 | 35.46 | |
Resistance 1 (R1) | 34.41 | 34.30 | 34.03 | 34.31 | 35.31 |
Pivot Point | 33.64 | 33.64 | 33.45 | 33.59 | 33.64 |
Support 1 (S1) | 32.68 | 32.98 | 32.30 | 32.58 | 31.57 |
Support 2 (S2) | 31.91 | 32.57 | 31.86 | 31.42 | |
Support 3 (S3) | 30.95 | 31.91 | 31.28 | ||
Support 4 (S4) | 30.85 |